An observational study in Chronic Venous Insufficiency, CVI, Chronic Venous Insufficiency C2 or Higher and Chronic Venous Disease of Lower Limbs, sponsored by King's College London. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by King's College London · Observational
Among 38 studies in Varicose Ulcer with a site in United Kingdom — 3 open to participants now, 6 under way, 1 of them phase 3. Varicose Ulcer · United Kingdom.
Among the 38 studies in Varicose Ulcer with a site in United Kingdom, this one is the only one that started in 2025, is one of 6 observational ones, and was the 37th registered.
369 studies on the registry are indexed under Varicose Ulcer; 77 are open to participants now.
This study's planned enrollment of 51 is below the median of 131 across 47 observational studies indexed under Varicose Ulcer.
Browse Varicose Ulcer studies →3 of the 38 studies in Varicose Ulcer with a site in United Kingdom are open now, in 3 countries. Each count lists the studies.
Of the 52 Varicose Ulcer studies recruiting now, 42 (81%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →38 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
Median enrollment 80 across the 32 interventional studies, 56 across the 6 observational. Of the 32 that completed or were terminated, 13 (41%) have results posted.
28 of 38 have an industry lead sponsor. The 10 most frequent:
King's College London is the lead sponsor of 520 studies on the registry; 126 are open to participants now.
King's College London has 1 study filed under Varicose Ulcer — fewer than ten, so there is no comparison to draw.
2 of the studies in Varicose Ulcer with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06489028Phase 3RHEACELL GmbH & Co. KGAllogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III) | 2027-04 |
| NCT05007301Firstkind LtdGeko™ Cross Therapy Registry - Wound | 2027-09 |
Among the 38 studies in Varicose Ulcer with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
The aim of this project is to define assessment criteria for chronic venous insufficiency (CVI) in people with dark skin tones. It will inform future interventions and modifications to practice for the assessment of CVI in people with dark skin tones in a nurse led intervention to improve patient assessment.
To achieve this there will be two parts to this study.
Work-package 1 - Mapping patient journeys and patient experiences 1.1 Objective
The objective of this work package is to:
1.2 Purpose Patient journeys will be used as a catalyst for change in the identification of CVI for people with dark skin tones. We also aim to learn from people with dark skin tones about how they recognised skin changes in their lower legs to further inform clinical assessment guidance and techniques.
1.3 Study design This part of the study is a qualitative interview study. This design ensures patients experience from their perspectives are captured.
Mapping the clinical journey from the patient perspective has significant potential to inform the redesign of new, patient centred models of care and service delivery and understanding delays in diagnosis. The areas identified within the interviews will enable future interventions to target failures in current clinical care and the narratives of patient experiences captured within the interviews will also be recorded to form the basis of trigger films or quotes that can be used within the co-design process of future interventions using a experience-based co-design approach.
Participants will also explain how they noticed skin changes in their own skin, to aid in the development of appropriate language and explanations of skin changes in this patient group in an appropriate way.
To achieve the objective each consenting participant will
1.4 Participants 1.4.1 Source of participants.
Participants will be recruited from any of the following :
Work package 2 - Informing skin assessment technique and medical photography 2.1 Objective
The primary objective of this work package is to:
The secondary objective is to:
2.3 Study design This part of the study is an analytical cross-sectional study of 15 patients which includes reviewing participating patients clinical notes. This design enables assessment information to be captured on participating individuals and analyse associations with assessment data from scan results to enable proof-of-concept of skin assessment techniques in people with dark skin tones.
To achieve this objective each consenting participant will
undergo the following:
The research nurse will also give their feedback of undertaking the assessments on each patient in their structured field notes documenting relevant dimensions of acceptability identified by Sekhon and colleagues (affective attitude, perceived effectiveness, self-efficacy).
2.4 Participants 2.4.1 Source of participants. Participants will be recruited from a clinical setting 2.4.2 Inclusion / Exclusion Criteria inclusion criteria
Work-package 1 - Mapping patient journeys and patient experiences Source of participants.
People with with chronic venous insufficiency, or their close family member, will be recruited from any of the following :
Work package 2 - Informing skin assessment technique and medical photography Source of participants. Participants will be recruited from clinical settings within our trust partner organization. This NHS Foundation Trust is the hub of the southeast Thames vascular network, based in London, UK.
Work-package 1 - Mapping patient journeys and patient experiences Participant inclusion criteria
Work package 2 - Informing skin assessment technique and medical photography Participant inclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participating in semi-structured interview exploring patient experience and patient journey of people with dark skin tones living with chronic venous insufficiency in the U.K. Number of people: 36
People with dark skin tones and known chronic venous insufficiency with up to date scan results of their blood flow seen by our trust partner (the hub of the southeast Thames vascular network) by either acute or community services. Number of people: 15
Work-package 1 - Patient experience
No quantitative outcomes will be assessed in the interview study to map patient journey and patient experience.
Time frame: Baseline
Work package 2 - Skin assessment of the lower limb
the clinical researcher / research nurse will follow guidance on assessing the skin in people with dark skin tones. The current guidance on this includes using touch (palpation) as well as visualising skin changes to feel for any temperature change or tightness, and asking the patient whether they have noticed any changes in appearance of have any symptoms such as pain, itching or sensation changes. Al In addition to the assessments recommended in existing clinical guidelines, there is an indication from our recent qualitative interviews with specialist staff, some clinicians have refined their skills and techniques to assist them to undertake, what they perceive to be, a more accurate assessment on people with dark skin tones. This includes several techniques that have not been reported elsewhere including the use of transillumination and extending the skin to visualize changes. All these assessments will be reported for each patient.
Time frame: Baseline
Work package 2 - Clinical (C) classification of the CEAP
This assessment will be based on the Clinical (C) classification of the CEAP, which is the most widely used tool for venous disease classification and recommended by international guidelines. These may not be readily observed in patients with dark skin tones, especially by non-specialist clinicians. The clinical researcher / research nurse will base their clinical interpretation of CEAP score based on their assessments of skin changes. Individual observations will be reported alongside the classification assigned. This scale denotes clinical classification of skin changes from C0 (no visible or palpable signs of venous disease) to C6 (an active venous ulcer).
Time frame: Baseline
Work package 2 - Venous Clinical Severity Score
This is a a widely used tool for rating clinical severity which guidance suggests should be considered in research on venous disease. The clinical researcher / research nurse will base their clinical interpretation of each component of the venous clinical severity score based on their assessments of skin changes and patient assessment. Individual observations will be reported alongside the classifications assigned. This scale scores several components such as pain, varicose veins, venous oedema, pigmentation, inflammation, induration, active ulcers, use of compression. Each question can score between 0 and 3 points, where more points equates to more severe.
Time frame: Baseline
Work package 2 - Wound photography under standard and modified conditions
These images will provide proof of concept whether skin photography techniques can be modified to improve skin changes associated with venous hypertension and chronic venous disease on people with dark skin tones. This following suggestions in previous research on skin assessment in people with dark skin tones that modifying the photographs is advantageous to assess for erythema associated with pressure damage in the laboratory setting. However, to date no research has considered whether this could be advantageous to assist in the detection of skin changes associated with CVI, or could be undertaken in the clinical setting.
Time frame: Baseline
Work package 2 - Patient experience
Patient perspective of undertaking these assessments. It will explore what they felt of these assessments to ensure patients feel these assessments are appropriate, they felt these are effective and whether they caused any unnecessary discomfort or inconvenience. Data will be collected qualitatively to capture patients perceptions, feelings and opinions.
Time frame: Follow up (less than 72 hours after data obtained)
Work package 2 - Clinican experience
Give their feedback of undertaking the assessments on each patient in their structured field notes
Time frame: Follow up (less than 24 hours after data obtained)
Plan to share: Yes — Data collected as part of this study will be stored in King's Open Research Data System (KORDS), providing long-term storage. This enables DOIs issued for long-term access and citation.
Supporting information: Study protocol
Time frame: The study protocol will be available once ethical approval is granted.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jan 2026, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.